Pfizer Stock News

It's selling shovels amid the gold rush in mRNA medicines.

J&J's (JNJ) Pharma unit is performing above market levels. The Consumer unit is improving. The Medical Devices unit is being hurt by soft recovery trends in medical procedures.

With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.

FDA approves AbbVie's (ABBV) Rinvoq for the treatment of moderate-to-severe ulcerative colitis in adults. This is the fourth indication for Rinvoq in the United States.

Benzinga has launched a “Bulls vs. Bears” March Madness competition to find out which stock will take home top honors by fan vote. What Happened: Coinciding with the 2022 NCAA Men’s Basketball T

Moderna's (MRNA) shares are rising presumably in anticipation of rising demand for its COVID-19 vaccine amid authorization for younger population and the fear of another global infection wave.

Alnylam Pharmaceuticals Inc said on Thursday it has separately filed lawsuits against Pfizer Inc and Moderna Inc , seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines.

Alnylam files patent infringement lawsuits against Pfizer, Moderna

Centogene N.V. (CNTG), a German biotech focused on rare disorders, announced on Thursday that the company agreed to expand its data access and collaboration agreement with the U.S

One of these companies even yields nearly 9% on its latest share price.

Q4 2021 revenue of $15.7 million , Adjusted EBITDA of $6.2 million and cash from operations of $4.0 million 2021 revenue of $60.0 million , Adjusted EBITDA of $26.3 million and cash from operations of $16.4 million Vascepa ® prescriptions grew 19% sequentially in Q4 2021 - amid continued COVID-19 disruptions 1,710 physicians have prescribed Vascepa, up 25% sequentially and up from 550 at the end of 2020. 6,100 patients have used Vascepa, up 21% sequentially and up from 2,000 at the end of 2020 HLS is in the final stages of the process for public plan reimbursement of Vascepa. Final outcome is expected within weeks. TORONTO , March 17, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS ), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the three- and twelve-month periods ended December 31, 2021 . All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated. Q4 & FISCAL 2021 FINANCIAL HIGHLIGHTS Q4 2021 revenue was $15.7 million compared to $16.5 million in Q4 2020.

As you approach your golden years, these companies could deliver the stability and growth that you need.

•Non-profit company to produce generic insulin that will be sold for $30 per vial as discussions of price-caps for lifesaving drug is sparked after State of the Union address Pfizer and Moderna, manufacturers of the two most popular used vaccines in the United States and much of the rest of the world, are expecting to […] The post Pfizer, Moderna set to make $51b in COVID-19 vaccine sales appeared first on The Guardian Nigeria News - Nigeria and World News .

The new biologics of the pharmaceutical company will be destined for first, second and third doses

In the latest trading session, Pfizer (PFE) closed at $52.92, marking a +1.36% move from the previous day.